MX2016004678A - Composiciones para el tratamiento del cancer. - Google Patents
Composiciones para el tratamiento del cancer.Info
- Publication number
- MX2016004678A MX2016004678A MX2016004678A MX2016004678A MX2016004678A MX 2016004678 A MX2016004678 A MX 2016004678A MX 2016004678 A MX2016004678 A MX 2016004678A MX 2016004678 A MX2016004678 A MX 2016004678A MX 2016004678 A MX2016004678 A MX 2016004678A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- treating cancer
- treatment
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 208000005017 glioblastoma Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361895308P | 2013-10-24 | 2013-10-24 | |
| PCT/US2014/061418 WO2015061229A1 (en) | 2013-10-24 | 2014-10-20 | Methods and compositions for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016004678A true MX2016004678A (es) | 2017-03-10 |
Family
ID=52993423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016004678A MX2016004678A (es) | 2013-10-24 | 2014-10-20 | Composiciones para el tratamiento del cancer. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9511050B2 (enExample) |
| EP (1) | EP3060207A4 (enExample) |
| JP (1) | JP6389884B2 (enExample) |
| KR (1) | KR20160065986A (enExample) |
| CN (1) | CN105848654B (enExample) |
| AU (1) | AU2014340398A1 (enExample) |
| CA (1) | CA2927148A1 (enExample) |
| IL (1) | IL245281A0 (enExample) |
| MX (1) | MX2016004678A (enExample) |
| RU (1) | RU2016114498A (enExample) |
| WO (1) | WO2015061229A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8232310B2 (en) * | 2006-12-29 | 2012-07-31 | Georgetown University | Targeting of EWS-FLI1 as anti-tumor therapy |
| DK2350075T3 (da) | 2008-09-22 | 2014-05-26 | Array Biopharma Inc | Substituerede imidazo[1,2b]pyridazinforbindelser som trk-kinase-inhibitorer |
| PT3106463T (pt) | 2008-10-22 | 2018-05-18 | Array Biopharma Inc | Compostos de pirazolo[1,5-]pirimidina substituídos como inibidores de cinase trk |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| RU2735545C2 (ru) | 2010-05-20 | 2020-11-03 | Эррэй Биофарма Инк. | Макроциклические соединения в качестве ингибиторов киназы trk |
| CA2869513C (en) | 2012-04-12 | 2020-07-07 | Georgetown University | Methods and compositions for treating ewings sarcoma family of tumors |
| AU2014340398A1 (en) * | 2013-10-24 | 2016-06-09 | Georgetown University | Methods and compositions for treating cancer |
| MX388564B (es) | 2014-10-09 | 2025-03-20 | Oncternal Therapeutics Inc | Compuestos de indolinona y usos de los mismos. |
| EP3218380B1 (en) | 2014-11-16 | 2021-03-17 | Array Biopharma, Inc. | Preparation of a crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
| KR102277538B1 (ko) * | 2015-06-08 | 2021-07-14 | 주식회사 대웅제약 | 신규한 헤테로 고리 화합물, 이의 제조 방법 및 이를 포함하는 약학적 조성물 |
| TN2019000271A1 (en) | 2015-10-26 | 2021-01-07 | Univ Colorado Regents | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| KR102514814B1 (ko) | 2016-03-31 | 2023-03-27 | 온크터널 테라퓨틱스, 인코포레이티드. | 인돌린 유사체 및 이의 용도 |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| IL304018A (en) | 2016-04-04 | 2023-08-01 | Loxo Oncology Inc | Liquid formulations of (S)-N-(5-((R)-2-(5,2-difluorophenyl)-pyrrolidine-1-yl)-pyrazolo[5,1-A]pyrimidin-3-yl)-3 -hydroxypyrrolidine-1-carboxamide |
| ES2952056T3 (es) | 2016-05-18 | 2023-10-26 | Loxo Oncology Inc | Preparación de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida |
| US10613088B2 (en) * | 2016-06-12 | 2020-04-07 | Mohammad Abdolahad | Method and system for metastasis diagnosis and prognosis |
| US10761081B2 (en) * | 2016-06-12 | 2020-09-01 | Mohammad Abdolahad | Method and system for metastasis diagnosis and prognosis |
| KR102282794B1 (ko) | 2016-07-29 | 2021-07-27 | 온크터널 테라퓨틱스, 인코포레이티드. | 인돌리논 화합물의 용도 |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| CN118147307A (zh) * | 2017-02-28 | 2024-06-07 | 梅约医学教育与研究基金会 | 用于表征来自人患者的样品的方法 |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| CN110845389A (zh) * | 2019-10-17 | 2020-02-28 | 袁健 | 一种新型i型拓扑异构酶抑制剂 |
| CN114057626B (zh) * | 2021-12-07 | 2023-06-30 | 山东第一医科大学(山东省医学科学院) | 一种吲哚-2,3-二酮的衍生物和制备方法、抑制recql4特异性表达的抗肝癌药物 |
| WO2026009227A1 (en) | 2024-07-04 | 2026-01-08 | Yeda Research And Development Co. Ltd. | Compositions for downregulating zeb2 in macrophages and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3483704D1 (de) | 1983-07-22 | 1991-01-17 | Du Pont | Phenylchinolinsaeure und derivate als antitumormittel. |
| DE69922997T2 (de) * | 1998-12-04 | 2005-12-15 | Neurosearch A/S | Verwendung von isatinderivaten als ionenkanalaktivierende mittel |
| CN1155572C (zh) | 2001-01-19 | 2004-06-30 | 中国人民解放军军事医学科学院毒物药物研究所 | 吲哚类衍生物及其抗肿瘤用途 |
| US20030157486A1 (en) | 2001-06-21 | 2003-08-21 | Graff Jonathan M. | Methods to identify signal sequences |
| EP3034510A1 (en) | 2004-04-30 | 2016-06-22 | Alnylam Pharmaceuticals Inc. | Oligonucleotides comprising a c5-modified pyrimidine |
| WO2006117414A1 (es) | 2005-04-29 | 2006-11-09 | Proyecto De Biomedicina Cima, S.L. | Modelo animal no humano de sarcoma |
| WO2008083326A2 (en) * | 2006-12-29 | 2008-07-10 | Georgetown University | Targeting of ews-fli1 as anti-tumor therapy |
| US8232310B2 (en) * | 2006-12-29 | 2012-07-31 | Georgetown University | Targeting of EWS-FLI1 as anti-tumor therapy |
| US8232410B2 (en) | 2007-04-20 | 2012-07-31 | The Research Foundation Of State University Of New York | Benzimidazoles and pharmaceutical compositions thereof |
| TW201346030A (zh) * | 2012-04-02 | 2013-11-16 | Gradalis Inc | 依汶氏(EWING’S)肉瘤雙功能shRNA設計 |
| CA2869513C (en) | 2012-04-12 | 2020-07-07 | Georgetown University | Methods and compositions for treating ewings sarcoma family of tumors |
| AU2014340398A1 (en) * | 2013-10-24 | 2016-06-09 | Georgetown University | Methods and compositions for treating cancer |
-
2014
- 2014-10-20 AU AU2014340398A patent/AU2014340398A1/en not_active Abandoned
- 2014-10-20 US US15/030,713 patent/US9511050B2/en active Active
- 2014-10-20 JP JP2016526034A patent/JP6389884B2/ja active Active
- 2014-10-20 WO PCT/US2014/061418 patent/WO2015061229A1/en not_active Ceased
- 2014-10-20 CA CA2927148A patent/CA2927148A1/en not_active Abandoned
- 2014-10-20 EP EP14855801.8A patent/EP3060207A4/en not_active Withdrawn
- 2014-10-20 CN CN201480071102.0A patent/CN105848654B/zh active Active
- 2014-10-20 MX MX2016004678A patent/MX2016004678A/es unknown
- 2014-10-20 KR KR1020167013692A patent/KR20160065986A/ko not_active Withdrawn
- 2014-10-20 RU RU2016114498A patent/RU2016114498A/ru not_active Application Discontinuation
-
2016
- 2016-04-21 IL IL245281A patent/IL245281A0/en unknown
- 2016-11-30 US US15/365,794 patent/US20170157089A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20170157089A1 (en) | 2017-06-08 |
| JP2016534084A (ja) | 2016-11-04 |
| IL245281A0 (en) | 2016-06-30 |
| CN105848654A (zh) | 2016-08-10 |
| CN105848654B (zh) | 2018-10-02 |
| EP3060207A4 (en) | 2017-04-12 |
| US9511050B2 (en) | 2016-12-06 |
| RU2016114498A (ru) | 2017-11-29 |
| CA2927148A1 (en) | 2015-04-30 |
| RU2016114498A3 (enExample) | 2018-08-13 |
| EP3060207A1 (en) | 2016-08-31 |
| AU2014340398A1 (en) | 2016-06-09 |
| JP6389884B2 (ja) | 2018-09-12 |
| US20160263086A1 (en) | 2016-09-15 |
| WO2015061229A1 (en) | 2015-04-30 |
| KR20160065986A (ko) | 2016-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016004678A (es) | Composiciones para el tratamiento del cancer. | |
| EA201591674A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
| MX366804B (es) | Translocaciones de la r-espondina y sus metodos de uso. | |
| MX2016002974A (es) | Eteres de arilo y sus usos. | |
| SG11201510751YA (en) | Composition and vaccine for treating prostate cancer | |
| MX2016007801A (es) | Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa. | |
| PH12021552742A1 (en) | Afucosylated anti-fgfr2iiib antibodies | |
| MX2015014431A (es) | Monoterapia con glucopiranosil lipido a para usarse en el tratamieto del cancer. | |
| MX2015009209A (es) | Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos. | |
| PH12016500164B1 (en) | Therapeutically active compounds and their methods of use | |
| BR112015029386A2 (pt) | uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer | |
| TW201611843A (en) | Methods of treatment with arginine deiminase | |
| PH12018502569A1 (en) | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | |
| GEAP201913925A (en) | Compositions and methods for treating surface wounds | |
| IN2014DN09228A (enExample) | ||
| MX377593B (es) | Composiciones para usar en el tratamiento de cáncer renal. | |
| MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
| IL241823B (en) | Preparations containing novyi .c and their uses for the treatment of cancerous tumors | |
| EA201591987A1 (ru) | Лечение злокачественной опухоли дигидропиразинопиразинами | |
| MX2016000131A (es) | Nanoparticulas polimericas de docetaxel para el tratamiento de cancer. | |
| EA032501B9 (ru) | Способы и композиции для содействия заживлению острой раны и хронической раны | |
| MX2017006026A (es) | Apilimod para uso en el tratamiento de cancer colorrectal. | |
| MX2015013021A (es) | 5-bromo-indirrubinas. | |
| MX2014012535A (es) | Terapia de combinacion de anticuerpos anti-mif y quimioterapeuticos. | |
| MX369455B (es) | Métodos mejorados para tratamiento de grano con ozono. |